Project OCTAV is designed to capture in situ images of the skin layers with a cellular resolution. It is used in conjunction with dermoscopy to provide more accurate diagnosis, leading to fewer biopsies of benign lesions and earlier detection of melanoma and non-melanoma skin cancers. It may also guide the surgery to provide more accurate presurgical margins, preventing unnecessarily large scars and reducing the risk of recurrence.
After a feasibility phase, covered by the SME Instrument Phase 1, successfully completed, DAMAE has developed and CE-marked a clinical LC-OCT device, which is being used within clinical trials throughout Europe, to validate the accuracy of LC-OCT diagnostics in onco-dermatology. Thanks to this H2020 funding, the company plans to scale-up the solution through industrialization and market access activities, implement its production and launch the product on the market. This project OCTAV has received funding from the European Union’s Horizon 2020 research and innovation programme, under approval number n° 850006.